Followers | 3819 |
Posts | 239982 |
Boards Moderated | 0 |
Alias Born | 07/30/2007 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, September 09, 2016 9:08:40 AM
7:39 AM ET 9/9/16 | MarketWatch
Shares of Lexicon Pharmaceuticals Inc. (LXRX) rallied a stunning 48% in premarket trade Friday, after the company reported positive results from a late-stage trial of a treatment for type 1 diabetes. The company said the Phase 3 trial of sotagliflozin met its primary endpoint, showing a statistically significant improvement in blood sugar control in patients with type 1 diabetes on a background of optimized insulin. The improvement was made without an increase in severe hypoglycemia, a serious health challenge in type 1 diabetes. Lexicon is working with Sanofi to develop the compound for use in type 1 and type 2 diabetes. Shares were up 15% in the year through Thursday's close, while the S&P 500 has gained 7%.
-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com
> Dow Jones Newswires
September 09, 2016 07:39 ET (11:39 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Recent LXRX News
- Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association • GlobeNewswire Inc. • 06/14/2024 12:00:00 PM
- Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024 • GlobeNewswire Inc. • 05/29/2024 11:30:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/16/2024 04:15:16 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/14/2024 09:05:01 PM
- New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction • GlobeNewswire Inc. • 05/14/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 08:05:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 08:04:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 08:03:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 08:01:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 08:00:44 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/10/2024 09:14:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 08:15:54 PM
- Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024 • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/02/2024 08:05:00 PM
- Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals • GlobeNewswire Inc. • 04/29/2024 01:00:00 PM
- Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024 • GlobeNewswire Inc. • 04/29/2024 11:00:00 AM
- Lexicon Pharmaceuticals to Host 2024 Investor Day • GlobeNewswire Inc. • 04/18/2024 12:00:40 PM
- Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 01:20:45 PM
- New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease • GlobeNewswire Inc. • 03/12/2024 12:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/11/2024 08:25:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 11:26:32 AM
- Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/11/2024 11:15:00 AM
- Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities • GlobeNewswire Inc. • 03/11/2024 11:05:00 AM
- Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM